In the News: 2019 Brings Drug Price Hikes
The price hikes affected both brand names and generics and mostly hit in the first week in January, when manufacturers typically raise prices, the report said. What the researchers noted was not typical was the large number of drug products affected by the hikes.
The study found that drug prices – while increasing across the board – were notably higher in large cities. For example, drugs cost nearly 17% more than the national average in New York City and 14% more than the average in San Francisco. Meanwhile, cities like Atlanta and Houston were spending 20% below the national average.
The reason for this geographic disparity in drug pricing could be cost of living – most goods tend to cost more in cities with higher costs of living. Researchers note that these cities also tend to have more high-cost pharmacies and fewer low-cost alternatives.
To learn more about the GoodRx study, read the complete article.
Hospital Drug Spend Also Rises
Much concern is focused on how rising drug prices affect individual consumers. However, hospitals and health systems are also feeling the strain in 2019. In the beginning of the year, the American Hospital Association, the Federation of American Hospitals, and the American Society of Health-System Pharmacists (ASHP) released a report titled, “Recent Trends in Hospital Drug Spending and Manufacturer Shortages.” It showed a 18.5% increase in average total drug spend per admission between FY2015 and FY2017.
Additionally, the report found:
- Inpatient drug spending increased 9.6%
- Outpatient drug spending increased 28.7%
- Hospitals experienced price increases in excess of 80% across different drug classes, including anesthetics, parenteral solutions, opioid agonists, and chemotherapy
- Payers couldn’t keep up with the costs, as hospital expenditures exceeded the Medicare reimbursement rate five-fold during the study period
To learn more, download the complete study.
You may also like:
When drug therapy fails to achieve its objectives, it is frustrating for both the patients, whose health and well-being is on the line, and the providers, who believed they were recommending the best possible care. Pharmacogeno...
Discussion of the value and scope of USP <800> standards; the definition of hazardous drugs, the associated types of potential exposure, and where exposure may occur; importance of assessment of risk; and the responsibili...
Filter by Type
Sign up to receive the latest news and information!